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Abstract: In medical practice, the effectiveness of fighting cancer is not only determined by 
the composition of the used drug, but determined by the administration method as well. As 
a result, having drugs with a suitable action profile is just a promising beginning, but 
without appropriate delivery methods, the therapy still can be ineffective. Finding the 
optimal biologic dose is an empirical process in medical practice; however, using 
controllers, an automated optimal administration can be determined. In this paper, we 
evaluate the effectiveness of different drug delivery protocols; using in silico simulations 
(like bolus doses, low-dose metronomic regimen and continuous infusion therapy). In 
addition, we compare these results with discrete-time controller-based treatments 
containing state feedback, setpoint control, actual state observer and load estimation. 
Keywords: antiangiogenic therapy; maximum tolerated dose; bolus dose; low-dose 
metronomic regimen; continuous infusion therapy; optimal biologic dose; discrete-time 
control; state feedback; setpoint control; actual state observer; load estimation 
1 Introduction 
1.1 Biomedical Background 
Tumor cells can appear in the human body after a somatic mutation. As tumor 
cells proliferate, the number of cells increase, and the tumor volume grows. This 
growth, however, is limited since blood supply is provided by the nearby 
capillaries, and if the tumor cells grow farther than the diffusion distance (150 
μm), nutrition and oxygen access decrease. In order to overcome this problem, 
tumor cells need their own blood supply. There are two main ways to form new 
blood vessels. The formation of the first primitive vascular plexus is called 
vasculogenesis, while the formation of new blood vessels from the preexisting 
J. Sápi et al. Potential Benefits of Discrete-Time Controller-based Treatments  
 over Protocol-based Cancer Therapies 
 – 12 – 
microvasculature is angiogenesis [1]. In the case of tumor growth, angiogenesis 
takes place, which is regulated by pro- and antiangiogenic factors. The most 
important proangiogenic factor is the vascular endothelial growth factor (VEGF) 
since it specifically regulates endothelial proliferation [2] which is essential for 
angiogenesis. Therefore, VEGF inhibition is an important therapeutic target [3]; 
and to control angiogenesis, anti-VEGF agents and other VEGF inhibitors are 
being used around the world [4]. However, the best angiogenic inhibition 
administration method is still unknown in clinical practice [5], thus an effective 
and automatic administration method is required. 
1.2 Background of the Control Problem 
We investigated a well-known tumor growth model under antiangiogenic therapy 
[6] and designed several continuous-time controllers like an LQ control method 
and state observer [7-9], flat control [10-12], modern robust control method [13-
15], feedback linearization method [16] and adaptive fuzzy techniques [17]. 
However, with the current scientific knowledge, there is no medical device which 
can handle continuous infusion cancer therapy [18]; hence we designed a discrete-
time control herein. 
2 Tumor Growth Model 
P. Hahnfeldt et al. created a model which describes tumor growth under 
angiogenic inhibition [6]. Assuming that after the injection, the level of the 
inhibitor in the bloodstream is equal to the amount of the injected inhibitor, the 
original third-order system was modified to a second-order system: 
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where the first state variable (x1) is the tumor volume [mm
3
], while the second 
state variable (x2) is the volume of the vasculature of the tumor [mm
3
]. The input 
of the model is the concentration of the injected inhibitor (g [mg/kg]). The first 
equation contains the λ1 parameter which describes the tumor growth rate (1/day). 
The change of the vasculature volume depends on three effects: a) the tumor can 
stimulate the already existing capillaries to form new blood vessels by the process 
of sprouting (parameter b [1/day]), b) endothelial cell death causes volume loss in 
vasculature (parameter d [1/(day·mm2]), c) the administration of antiangiogenic 
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drug causes volume loss in vasculature as well (parameter e [kg/(day·mg]). In the 
case of Lewis lung carcinoma, and using endostatin as antiangiogenic drug, the 
parameters are the following [1]: λ1 = 0.192 1/day, b = 5.85 1/day, d = 0.00873 
1/day·mm2, e = 0.66 kg/(day·mg). 
3 Protocol-based Cancer Therapies 
3.1 Cancer Protocols in the Light of the Dosage Problem 
As it was discussed previously, there is no best way for antiangiogenic drug 
administration in clinical practice. There are three main methods which are used; 
however, both ones have advantages and disadvantages. Bolus dose (BD) 
administration means that the patient receives drug boluses on given days, and 
between the injections, the treatment has rest periods when there is no drug 
administration at all. The amount of injected dose can be the Maximum Tolerated 
Dose (MTD) or any lower dose. After an MTD injection, the treatment should 
include an extended rest period in order to avoid adverse events. Instead of bolus 
doses, anticancer drugs can be delivered over prolonged periods using low-doses, 
this therapy is called as Low-Dose Metronomic (LDM) regimen. Of course, in this 
case the rest periods can be shorter; but the real question is to find the Optimal 
Biologic Dose (OBD) which results in the best therapeutic efficacy. Finally, in 
clinical environment continuous infusion therapy is feasible (e.g. using mini-
osmotic pumps), but there is no portable device yet. Clinical experiments have 
shown that low-dose administration therapies have better therapeutic efficacy than 
bolus dose injections, and continuous infusion therapies have even better results 
[19]. 
3.2 Simulation Results of the Protocol-based Cancer Therapies 
The effect of bolus dose administration, low-dose metronomic regimen and 
continuous infusion therapy was investigated in silico, using the modified 
Hahnfeldt-model described by Eq. (1)-(3). The total administered inhibitor 
concentration is 300 mg/kg, and treatment period is 15 days in every simulation, 
in order to get comparable results. Simulations start from the lethal steady-state of 
the model when the initial value of tumor volume (x1(0)) and vascular volume 
(x2(0)) are 1.734∙10
4 
mm
3
. Four different scenarios were examined [20] (left side 
of Figure 1). 
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Figure 1 
Protocol based therapies (treatment period is 15 days) 
a) Therapy P1: bolus doses with maximum tolerated dose (BD MTD) 
Therapy: 100 mg/kg bolus injected for one hour; treatment days: 1st, 6th and 12th days; rest periods: 5 
days. Total inhibitor concentration: 300 mg/kg, steady state tumour volume: 16330 mm3. 
b) Therapy P2: bolus doses (BD) 
Therapy: 20 mg/kg bolus injected for one hour; treatment days: every day of the therapy; rest periods: 
23 hours. Total inhibitor concentration: 300 mg/kg, steady state tumour volume: 15580 mm3. 
c) Therapy P3: low-dose metronomic regimen (LDM) 
Therapy: 2.5 mg/kg infusion administered for one day; treatment days: 1st, 4th ,7th, 10th, 13th days; rest 
periods: 2 days. Total inhibitor concentration: 300 mg/kg, steady state tumour volume: 15660 mm3. 
d) Therapy P4: continuous infusion therapy (cont) 
Therapy: 0.8333 mg/kg/h continuous infusion administration during the whole therapy; without rest 
periods. Total inhibitor concentration: 300 mg/kg, steady state tumour volume: 15360 mm3. 
Therapy P1 (BD MTD). The therapy using bolus doses with maximum tolerated 
dose contains 100 mg/kg boluses which are injected for one hour. Treatment days 
are the 1
st
, 6
th 
and 12
th 
days (3 times); between these days, the therapy contains 5 
days long rest periods. 
Therapy P2 (BD). In this case lower bolus doses are used than the maximum 
tolerated dose. 20 mg/kg bolus is injected for one hour every day of the therapy 
(15 times). The treatment contains 23 hour rest periods. 
Therapy P3 (LDM). Low-dose metronomic regimen is carried out with 2.5 mg/kg 
infusions which are administered for one day. Treatment days are the 1
st
, 4
th
 ,7
th
, 
10
th 
and 13
th 
days (5 times). The therapy contains 2 day rest periods. 
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Therapy P4 (cont). Continuous infusion therapy is carried out with               
0.8333 mg/kg/h continuous infusion during the whole treatment, without rest 
periods. 
The right side of Figure 1 depicts the outputs of the tumor growth model, using 
Therapy P1 - Therapy P4 as inputs. Similarly to the clinical experimental results, 
simulations show that the less effective therapy is the bolus doses with maximum 
tolerated dose (BD MTD). Tumor volume reduction is not effective (steady state 
tumor volume is 16330 mm
3
), and beside this, side-effects can occur and quality 
of life (QoL) of the patient decreases due to the therapy. Lower bolus doses (BD) 
cause continuous slight reduction of the tumor volume, however this is not 
significant (steady state tumor volume is 15580 mm
3
). Another disadvantage of 
this method is the resulting high frequency oscillation-like characteristics of the 
vascular volume. Low-dose metronomic administration (LDM) has similar results 
as BD in terms of tumor volume reduction (steady state tumor volume is       
15660 mm
3
) and oscillation-like characteristics of the vascular volume; however, 
the oscillation frequency and amplitude are lower which can be more tolerable for 
the patient. The most effective treatment is the continuous infusion therapy (cont) 
since it results in the lower steady state tumor volume (15360 mm
3
) and the 
change of the vascular volume is a smooth curve. In addition, due to the extremely 
low dosage, continuous infusion therapy has virtually no side-effects. 
4 Discrete-Time Controller-based Treatments 
The modified Hahnfeldt-model describes a nonlinear system, which has to be 
linearized due to controller design aspects. We applied operating point 
linearization in the g0 = 0 operating point. The resulting LTI (linear time 
invariant) system using state space representation is 
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4.1 Discrete-Time Controller Design with State Feedback, 
Setpoint Control, Actual State Observer and Load 
Estimation 
Taking into account a feasible discrete-time system, the state space equations are 
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The controllability and observability matrices of the discrete-time system are 
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where n is the dimension of the state variables. Since for every nonzero operating 
point, the matrices are full rank, the system is controllable and observable in every 
operating point. 
In order to find optimal solutions, we used the LQ control method as state 
feedback to minimize the tumor volume (x1) using the lowest possible control 
signal. The discrete-time cost function containing the positive definite Q and R 
weighting matrices is 
 
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As our aim was to minimize the square of the output (x1
2
 = y
2
), the Q matrix is the 
following: 
.CCQ T    (15) 
Acta Polytechnica Hungarica Vol. 14, No. 1, 2017 
 – 17 – 
The sought K feedback matrix of the discrete-time LQ problem can be found using 
the P solution of the Discrete Control Algebraic Ricatti Equation (DARE): 
  dTddTd PABPBBRK
1
  (16) 
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(17) 
For setpoint control, we assume that the reference signal is constant. The control 
structure is needed to be extended by two matrices (Nx and Nu) in order to use 
nonzero reference signal. The values of these matrices can be calculated as 
follows: 
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where n is the dimension of the state variables, while m is the dimension of the 
inputs (and outputs). 
As the vascular volume is non-measurable, we designed an actual state observer to 
estimate this state variable. We have verified that the matrix MoAd is full rank, thus 
the discrete-time system is observable with an actual observer described by the 
following difference equation: 
.ˆˆ 11   iiii HuGyxFx  (19) 
The F, H and G parameter matrices of the observer can be calculated as follows: 
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where φF(Ad
T
) refers to the characteristic polynomial of the matrix F evaluated at 
the matrix Ad
T
. 
Assuming that a disturbance reduced to the input of the system can occur (load 
change), we designed load estimation as well. The system was extended by the 
disturbance modeled as a constant state-variable that adds up to the input of the 
original model. The state feedback and the setpoint control were designed for the 
original system; however, the actual state observer was designed for the extended 
system. As a consequence, the difference equation of the state observer is 
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where 
dxˆ is the estimation of the disturbance. 
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Figure 2 depicts the whole block diagram of the closed-loop discrete-time control 
system containing state feedback, setpoint control, actual state observer and load 
estimation. Please note that saturation is used before the input of the tumor model 
in order to avoid negative or too high input values due to physiological aspects.  
 
Figure 2 
Block diagram of the discrete-time control containing state feedback, setpoint control, actual state 
observer and load estimation 
4.2 Simulation Results of the Discrete-Time Controller-based 
Treatments 
Using discrete-time controller, the treatment can contain bolus doses, low-dose 
metronomic parts and continuous periods as well. In order to get comparable 
results with the protocol based therapies, the treatment period was chosen to be 15 
days. Parameters of the discrete-time controllers were chosen according to [21]. 
The operating point of the linearization is x1= x2=10 mm
3
, the R weighting matrix 
used in the design of the LQ control is 1. In order to get steady state tumor 
volumes close the protocol based cancer therapies’ values, the reference signal is 
13000 mm
3
. Since protocol based cancer therapies do not have disturbance, the 
disturbance is 0% in the case of discrete-time controllers. Three different 
scenarios were examined in the light of the saturation level (left side of Figure 3). 
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Figure 3 
Discrete-time controller based therapies (treatment period is 15 days) 
Parameters: operating point: 10 mm3; R: 1; reference signal: 13000 mm3; disturbance: 0%. 
a) Therapy C1: saturation = 100 mg/kg 
Total inhibitor concentration: 138 mg/kg, steady state tumour volume: 9870 mm3. 
b) Therapy C2: saturation = 20 mg/kg 
Total inhibitor concentration: 56 mg/kg, steady state tumour volume: 11360 mm3. 
c) Therapy C3: saturation = 2.5 mg/kg 
Total inhibitor concentration: 30 mg/kg, steady state tumour volume: 13153 mm3. 
Therapy C1 (sat = 100). The saturation level was chosen to be the maximum 
tolerated dose (Therapy P1). The control signal mostly contains MTD boluses; the 
administered boluses have lower amplitude only in a few cases. The treatment 
contains 3 rest periods, the longer one is approximately 6.5 days and it appears in 
the middle of the therapy. 
Therapy C2 (sat = 20). This therapy has the same saturation level as Therapy P2 
(BD). Due to the lower saturation level compared to Therapy C1, this treatment 
has shorter rest periods; however, the characteristics of the treatments are similar. 
In the beginning of the therapy, bolus doses follow each other frequently for 
approximately 7.5 days, and in some cases the boluses are smaller than the level 
of saturation. 
Therapy C3 (sat = 2.5). Finally, the saturation level was chosen to be equal to the 
input of the continuous infusion therapy (Therapy P3). The resulting treatment 
contains only one rest period in the very beginning of the treatment. After that a 
continuous administration can be obtained for approximately 8 days, which is 
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followed by a phase where bolus doses follow each other frequently (the 
amplitude of these boluses is the saturation level in every case). 
The right side of Figure 3 depicts the outputs of the tumor growth model, using 
Therapy C1 - Therapy C3 as inputs. Using Therapy C1, the total inhibitor 
concentration is 138 mg/kg, which is the highest total drug administration among 
the discrete-time controller based therapies. The achieved “steady state”1 tumor 
volume is 9870 mm
3
 (since at the end of the treatment, an undershoot can be 
observed). The total inhibitor concentration in Therapy C2 is 56 mg/kg, which is 
substantially lower in comparison with Therapy C1; however the steady state 
tumor volume is comparable (11360 mm
3
). Finally, Therapy C3 has resulted in the 
lowest total inhibitor concentration (30 mg/kg), and the achieved steady state 
tumor volume is 13153 mm
3
 in this case. 
Conclusions 
The efficacy of the therapies are compared and evaluated based on the achieved 
total inhibitor concentrations and steady state tumor volumes (Figure 4). During 
the protocol based therapies, the same amount of inhibitor was administered in 
total. As a consequence, the comparison is quite trivial: the smaller the steady 
state tumor volume, the better the therapy. Bolus doses with maximum tolerated 
dose (BD MTD) is the less effective treatment; bolus doses with lower boluses 
(BD) and low-dose metronomic regimen (LDM) are better; however, the best 
method is the continuous infusion therapy (cont) from the protocol based 
therapies. Nevertheless, discrete-time controller based therapies show better 
performance regardless of the saturation value. The choice between these 
therapies depends on the medical preferences and constraints. Having a patient 
who can tolerate MTD, and knowing that the aim is the fastest tumor reduction, 
we have to choose 100 mg/kg saturation (sat = 100). If we would like to find a 
trade-off solution, 20 mg/kg saturation (sat = 20) is the most appropriate choice. 
However, if slower tumor reduction is desired and/or patient does not tolerate the 
inhibitor well, our choice is the 2.5 mg/kg saturation level (sat = 20). 
                                                          
1
  In fact, in most of the cases the output of the tumor growth model does not reach the 
steady state at the end of the simulation; however, as we would like to express the 
effectiveness of the control in terms of tumor reduction, we use the “steady state” for 
the final state of the investigated control and we specify its value. 
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Figure 4 
Comparison of the therapies as functions of total inhibitor concentration and steady state tumour 
volume 
Protocol based therapies: bolus doses with maximum tolerated dose (BD MTD), bolus doses (BD), 
low-dose metronomic regimen (LDM), continuous infusion therapy (cont). Discrete controller based 
therapies: saturation: 100 mg/kg (sat = 100), saturation: 20 mg/kg (sat = 20),  
saturation: 2.5 mg/kg (sat = 2.5). 
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